CORTAnother lawsuit, another headache
Corcept Therapeutics is back in the legal crosshairs. Portnoy Law Firm announced a class action on behalf of investors who bought Corcept securities between October 31, 2024 and December 31, 2025, saying the company misled investors around relacorilant and the FDA’s review.
What’s the beef?
The complaint centers on Corcept’s December 31, 2025 disclosure that the FDA had issued a Complete Response Letter for relacorilant in hypercortisolism. According to the lawsuit, the agency said it couldn’t reach a favorable benefit-risk call without more evidence of effectiveness — which is corporate-speak for “not yet, try again.”
Why you should care
For investors, this is the kind of news that can linger like a bad sequel. The stock already dropped more than 50% on the CRL revelation, and now there’s fresh litigation risk layered on top. That can keep pressure on sentiment even if the science story eventually improves.
Big picture
Lawsuits don’t always change the fundamental business overnight, but they can add legal costs, management distraction, and a whole lot of uncertainty. For a biotech name already dealing with a regulatory gut punch, that’s not exactly the kind of company you want at your brunch table.